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Abstract
Objective—Initiation of antiretroviral therapy (ART) during tuberculosis (TB) treatment 
improves survival in TB-HIV co-infected patients. In patients with CD4+ counts <50cells/mm3, 
there is a substantial clinical and survival benefit of early ART initiation. The purpose of this 
study was to assess the costs and cost effectiveness of starting ART at various time points during 
TB treatment in patients with CD4+ counts ≥50cells/mm3.
Methods—In the SAPiT trial, 642 HIV-TB co-infected patients were randomized to three arms, 
either receiving ART within 4 weeks of starting TB treatment (early treatment arm; Arm-1), after 
the intensive phase of TB treatment (late treatment arm; Arm-2), or after completing TB treatment 
(sequential arm; Arm-3). Direct healthcare costs were measured from a provider perspective using 
a micro-costing approach. The incremental cost per death averted was calculated using the trial 
outcomes.
Results—For patients with CD4+ count≥50cells/mm3, median monthly variable costs per patient 
were $116, $113 and $102 in Arms-1, -2 and -3, respectively. There were 12 deaths in 177 
patients in Arm-1, 8 deaths in 180 patients in the Arm-2 and 19 deaths in 172 patients in Arm-3. 
While the costs were lower in Arm-3, it had a substantially higher mortality rate. The incremental 
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cost per death averted associated with moving from Arm-3 to Arm-2 was $4199. There was no 
difference in mortality between Arm-1 and Arm-2, but Arm-1 was slightly more expensive.
Conclusions—Initiation of ART after the completion of the intensive phase of TB treatment is 
cost effective for patients with CD4+ counts≥50cells/mm3.
Introduction
Tuberculosis (TB) is a leading cause of death among human immunodeficiency virus (HIV) 
infected patients.1 In Africa, 46% of -TB patients are HIV-positive 2 and in South Africa 
TB-HIV comorbidity is estimated at 73%3.
Initiation of antiretroviral therapy (ART) during TB treatment improved survival in TB HIV 
co-infected patients.4 Whilst severely immunosuppressed patients (CD4+ count 
<50cells/mm3) have better survival with early initiation of ART, the timing of ART 
initiation during TB treatment in patients with higher CD4+ counts is less clear.5,6
Based partly on the Starting Antiretroviral Therapy at Three Points in TB (SAPiT) study,4 
World Health Organisation7 and South African guidelines8 recommended in 2010 that TB-
HIV co-infected patients receive ART within 8 weeks of commencing TB treatment. In 
2012, both guidelines were updated recommending that all HIV-positive TB patients initiate 
ART immediately, irrespective of CD4+ count.9,10
Given the extent of the HIV-epidemic in South Africa,11 the large number of HIV- TB co-
infected patients eligible for ART, the budgetary implications of these changes in ART 
treatment guidelines are far-reaching.
Information on the cost of starting HIV treatment during TB treatment is vital for budgeting 
in countries where scale-up of early ART and TB care is required due to large numbers of 
co-infected patients. Extensive research has been done on the cost and cost-effectiveness of 
ART, ART provision, monitoring strategies, and regimen choices in sub-Saharan 
Africa.12–21 However, no studies were found that examined the comparative costs or cost-
effectiveness of different timing of ART initiation in TBtherapy for co-infected patients.22
Integration of HIV and TB services has the potential to save money through shared 
utilization of resources, such as monitoring and evaluation, avoidance of duplicate testing, 
medicine procurement, laboratory equipment, infrastructure and human resources.23–25 
Starting ART during TB treatment could also increase cost, as ART is provided to more 
patients and may require additional resources, such as infrastructure and staff training.23
Effectiveness and cost are both important considerations when determining the value of 
starting ART during TB treatment, especially in resource limited settings where efficient 
allocation of health care resources is necessary. While cost analysis methodologies quantify 
resources used for health interventions, thus enabling budgeting and planning, they do not 
inform about the overall value of interventions in terms of years of life saved. Cost-
effectiveness analysis weighs up both the costs and effectiveness of starting ART during TB 
treatment. Given the important budgetary implications of changes in ART eligibility for 
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high-burden countries, consideration of costs may be of benefit in guiding the timing of 
ART.
The purpose of this study is to assess the costs and cost-effectiveness of initiating ART with 
TB treatment (early treatment), at the end of the intensive phase of TB treatment (late 
treatment) or upon completion of TB treatment (sequential treatment), for adult patients co-
infected with TB and HIV with CD4 counts ≥50cells/mm3.
Methods
The SAPiT trial, conducted between 2005 and 2010, was a randomized, open-label, 
controlled clinical trial in patients co-infected with TB and HIV with CD4+ 
counts<500cells/mm3. The study design, ART and TB regimens and eligibility criteria have 
been described elsewhere.4,6 Patients were recruited at a municipal TB outpatient clinic 
where TB treatment was provided. HIV treatment was provided at an outpatient research 
clinic co-located with the TB outpatient clinic but in a different area with a different clinical 
team. Patients were randomized to three arms: initiate ART within 4 weeks following the 
initiation of TB treatment (Early treatment: Arm-1), within the first 4 weeks of the 
continuation phase of TB treatment (Late treatment: Arm-2) or after the completion of TB 
therapy (Sequential treatment: Arm-3). Each patient was followed for 18 months. Patient 
characteristics are described elsewhere. 4,6
All patients gave written informed consent. The trial was approved by the Biomedical 
Research Ethics Committee of the University of KwaZulu-Natal (E107/05) and the South 
African Medicines Control Council (20060137).
Data collection
Variable financial costs were estimated using a micro-costing approach from randomization 
onwards. The costs included were ART and non-ART medication costs, laboratory test 
costs, radiographs, outpatient consultations and hospitalization costs. Resource utilization 
was captured at the patient-level. Table 1 summarizes unit costs in US dollars ($). The 
average exchange rate for 15 December 2009 was used (7.47 South African Rands per US 
Dollar, www.xe.com).
Calculation of costs
The cost of voluntary counseling and testing, screening and baseline consultations, TB 
diagnostics, TB treatment, capital costs, fixed costs and overhead costs were excluded as 
they were common to all patients and did not vary by study arm. The decision to exclude 
these costs was guided by principles provided by Drummond et al (1997).26 Total cost in 
this study is thus an underestimation of the true cost. Excluding the costs of TB treatment 
was appropriate as there was no statistically significant difference in the length of TB 
treatment, type of treatment and incidence of multi drug resistant (MDR) TB between arms.
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Medication
Medication use, including start and stop dates, was documented in study records. ART doses 
were specified, and for other medications standard doses were assumed. Provincial ART 
tender prices (valid to December 2010) were used to cost ART. Private sector prices were 
used for enteric-coated didanosine (Videx EC®), as this was not available in the public 
sector. Public sector prices obtained from facility-level requisitions in February 2009 (where 
available) or private sector prices (obtained from the Mediscor PBM product database) were 
used for non-ART medications.
Laboratory tests
CD4+ count and viral load tests were recorded in patient files. Electronic results for safety 
laboratory tests were obtainable from February 2007to the end of the study. Only 347 
patients (285 with CD4+ count>=50) had electronic laboratory data for the entire study 
period. This laboratory cost sample included a disproportionately low number of patients 
who did not initiate ART (12% in the sample, 22% overall), and a disproportionally high 
number who experienced immune reconstitution syndrome (IRIS) (18% in the sample, 13% 
overall). To overcome the problem of missing data, while addressing sources of potential 
bias, conditional mean imputation by category of patient was used to impute laboratory test 
costs for the remaining 296 patients.
The categories used in the imputation were defined by arm, presence of IRIS, ART initiation 
and CD4 category (CD4+ counts<50cells/mm3 or CD4+ counts>50cells/mm3). Three 
outliers (with laboratory costs of greater than USD 1339) were excluded from the process of 
imputation in order to reduce potential bias. These patients remained in the overall patient 
sample, as these laboratory costs did not appear to be erroneous. The cost calculated for each 
subgroup was then applied to all patients with those characteristics who did not have 
laboratory data recorded.
The 2009 public sector price (charged by the National Health Laboratory Service) was used 
for all laboratory tests . The costs of documented radiographs were included. To make the 
results of this analysis more generalizable to primary health care settings where ART and 
TB treatment are usually provided all tertiary level laboratory tests were excluded from the 
calculation of laboratory test cost.
Labor and overhead costs
Outpatient consultations (number and type) were recorded in patient files. Interviews were 
conducted with a sample of staff to determine the time taken for different types of clinical 
consultations. These time estimates were multiplied by the average hourly public sector 
salary per staff type to determine staff costs per consultation. Department of Public Service 
and Administration 2009 Salary data (with effect 1 April 2009) was obtained from KZN 
Department of Health directly. Salaries included all benefits, such as pension and leave. 
Where specific roles did not exist within the public sector, CAPRISA salaries were used. 
The cost per different type of consultation was calculated.
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Hospital costs
Dates of hospital admission and discharge were recorded in patient files. Records were 
reviewed to determine resource use during hospitalization, including procedures performed, 
use of intravenous fluids and blood products and level of hospital and ward admitted to. 
Data on medications prescribed and laboratory tests performed in hospital were incomplete 
and were not used, instead prices per inpatient day and procedures performed in a public 
sector hospital from the 2009 Uniform Patient Fee Schedule (UPFS)27 were used. These 
prices are flat fees charged to patients with medical insurance who make use of public sector 
hospitals and are calculated to cover the estimated cost of consumables (with the exception 
of some high cost theatre and ward consumables), medication, hospital overheads, cost of 
support and medical staff. The prices exclude discharge medication, medication not on the 
essential drug list, anaesthetic and laboratory tests. Blood products were charged at the 
South African National Blood Service rate to public sector patients (SANBS State patient 
price list, 2009, www.sanbs,gov.za). Hospital costs include the cost of transportation to 
hospital and the cost of staff time spent referring patients. Several simplifying assumptions 
were made; for example, ward admitted to was inferred from information available, blood 
transfusions were assumed to have consisted of two units, costs of procedures and 
intravenous drugs were not included, and patients admitted to high care were assumed to 
have spent 50% of the stay in high care, the rest in a general ward. Assumptions made are 
expected to bias hospitalization costs downward. In the sensitivity analysis, the cost of 
procedures and intravenous drugs were included in hospitalization cost.
Analysis
Direct healthcare costs were measured from a provider perspective. Each resource used by 
each patient was multiplied by its unit cost and summed to determine the total cost per 
patient and per arm. The median cost per patient per month was calculated by dividing the 
total cost per patient by the number of months of follow-up. Discounting was not used, as 
the treatment spanned a short period and the timing of costs and benefits was similar across 
arms. To adjust for inflation 2009 prices were used throughout.
The outcome measure was all-cause mortality at 18 months using Kaplan-Meier methods. A 
simple patient-level micro costing model was developed in OpenOffice Calc (version 3.2) to 
combine data and calculate total variable cost per patient and patient month. The 
incremental cost per death averted was calculated over 18 months, by calculating the ratio of 
incremental total variable cost to incremental number of deaths averted between arms.26 The 
three treatment options were compared based on total cost and number of deaths associated 
with the treatment option. Any dominated options (treatment options with higher cost and 
lower effectiveness than the next alternative) were eliminated. Fisher’s exact test was used 
with categorical data, and Wilcoxon two-sample test or Kruskal-Wallis test with continuous 
data. Data were analysed in SAS (version 9.2).
One-way sensitivity analysis was used to test the implications of lower ART, lower viral 
load and laboratory test costs and alternative costs per inpatient day on the cost per patient 
month. Scenario analysis was conducted to evaluate the impact of several key assumptions 
Naidoo et al. Page 5
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 August 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
on the model. The cost of laboratory tests received particular attention as these were inflated 
due to the frequency and comprehensiveness of laboratory safety monitoring within a 
clinical trial setting.
Some data were missing in non-ART medications and in detailed hospitalization data 
(procedures, use of intravenous fluids, ward). Where duration and dosage information was 
missing, standard duration and dosage for the indication was assumed. Non-ART medication 
costs were small and even if incorrectly estimated, would not impact overall results. Data 
used were from December 2009. A previous publication was based on earlier incomplete 
interim data.4
Results
The SAPiT trial enrolled 642 patients and demonstrated a 56% reduction in mortality 
(hazard ratio:0.44, 95% confidence interval (CI):0.25–0.79,p=0.003) among patients 
initiating ART during TB treatment compared to after the completion of TB treatment.4 No 
difference in mortality was found between patients randomized to Arm-1 and Arm-2 
(incidence rate ratio=0.96, 95%CI:0.44–2.10), except in patients with CD4+ 
counts<50cells/mm3.6 Mortality rates in patients with CD4+ counts ≥50cells/mm3 was 
5.6/100 person years (95%CI:2.9–9.8) in Arm-1; 3.8/100 person years (95%CI:1.7–7.6) in 
Arm-2, and 10.0/100 person years (95%CI:6.4–15.7) in Arm-3.4,6 The mortality benefit was 
pronounced in patients with CD4+ counts<50 cells/mm3 and cost effectiveness arguments 
were not relevant in this subgroup. Consideration of cost-effectiveness is appropriate in 
choosing the optimal strategy for patients with CD4+ counts≥50cells/mm3. While all results 
are for patients with CD4+ counts≥50cells/mm3, the sub-group analysis of costs per arm in 
patients with <50 cells/mm3 is presented in Table 3. Loss to follow-up was 8.9%, 11.6% and 
13.1% in the three treatment arms.
The median monthly variable cost per patient was $116 (Arm-1), $113 (Arm-2) and $102 
(Arm-3), p<0.001. Arm-1 and Arm-2 had similar costs and mortality . Although costs in 
Arm-3 were the lowest, this arm had the highest mortality. Incremental cost per death 
averted in Arm-2, compared to Arm-3, was $4199 (Figure 1). Switching from sequential 
ART (ART offered at the end of TB treatment) to offering ART at the end of the intensive 
phase of TB treatment amounted to a cost of $4199 per death avoided. Arm-1 has slightly 
higher mortality than Arm-2, while Arm-1 is also marginally more expensive. This means 
that Arm-1 is dominated by Arm-2, and Arm-2 is the better choice both in terms of cost and 
mortality outcomes.
The costs of treating co-infected patients comprise four components: drugs, laboratory 
testing, outpatient care and hospitalization. Laboratory investigations, driven largely by 
research protocol safety requirements, contributed the largest proportion of variable cost in 
all three treatment arms (35.5% in Arm-1, 43.0% in Arm-2 and 10.7% in Arm-3. CD4+ 
count and viral load tests contributed between 10.6% and 12.2% to total variable costs, 
depending on arm. The number of CD4+ count and viral load tests performed was higher in 
Arm-2 than in the other two arms. Spending on laboratory tests was significantly higher in 
Arm-2 than in Arm-1 (p=0.005). Baseline CD4+ count <50cells/mm3 and presence of IRIS 
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significantly increased spending on laboratory tests (p<0.01). Spending on laboratory testing 
was higher for patients who did not initiate ART due to abnormalities in safety laboratory 
results since these patients required repeated testing. The cost of ART was the second largest 
contributor to total variable costs in Arm-1 (32.4%) and Arm-2 (28.7%), while it contributed 
only 17.6% to total costs in Arm-3. Outpatient consultations made up between 18.3 1nd 
19.7% of total costs across the arms. Hospitalization cost was the third largest cost in Arm-3 
(Table 2).
The median cost of consultations was similar across arms. The only difference in length of 
consultations was for the ART initiation visit, which was longer in Arm-1.
Hospitalizations comprised 12.9%, 7.7% and 22.4% of the total variable costs for 
Arms-1,-2, and-3, respectively. Both mean and median costs per patient hospitalized were 
highest in Arm-3. The median cost per patient hospitalized was $564 in Arm-1, $815 in 
Arm-2 and $1295 in Arm-3. The mean cost of hospitalization per patient hospitalized was 
much higher: $1603 in Arm-1, $1086 in Arm-2 and $2195 in Arm-3. The costs of 
hospitalization were more variable than other costs.
Most hospital admissions (89.6%, 120/134) were to a general ward, 9.7% (13/134) were to 
high care, and 0.7% (1/134) to intensive care; 62.7% (84/134) were admitted to secondary 
level hospitals. Procedures were recorded for 60.4% (81/134) of hospitalizations: these were 
procedures not requiring an operating theatre (54.5%, 54/99), radiological (20.2%, 20/99), 
minor surgical (20.2%, 20/99) and major surgical (5.1%, 5/99) procedures. The most 
common procedures performed were lumbar puncture, CT scan, administration of 
intravenous fluids for rehydration, radiograph and ultrasound. The median cost per 
procedure was $20. General ward costs accounted for 78% of total hospital costs.
The costs in Arm-2 were similar to costs in Arm-1 and patient survival was similar. Patients 
in the late treatment arm had the lowest number of hospitalizations, serious adverse events 
and IRIS; which are recognized cost drivers in the provision of TB and HIV services.
Over 18 months, Arm-1 was the most expensive ($1882), followed by Arm-2 ($1840) and 
Arm-3 ($657, p<0.001). The lower cost in Arm-3 was driven by shorter duration of ART 
provision, which lowered the cost of ART. The median cost of ART in Arm-3 was less than 
half the cost of ART in Arm1.
Sensitivity analyses showed that the median cost per patient month is not affected by 
changes in several key assumptions and changes in key prices (Table 4). While some 
scenarios resulted in much lower cost estimates, the trends between the arms remained 
similar. Costs per patient month were most sensitive to changes in ART prices and costs of 
investigations. Changes in the price of viral load testing made little difference. The 
difference in costs between Arms-1 and-2 was small when ART prices were reduced, but 
both strategies were still more expensive than Arm-3. The magnitude of the cost differences 
between the strategies did not change when the costs of laboratory testing were reduced. 
New ART tender prices have been negotiated since starting this study. The median cost per 
patient month was slightly lower when using these prices (Table 4).
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Discussion
The timing of ART initiation during TB care has implications for quality and cost of health 
service provision. In patients with CD4+ counts <50cells/mm3, the survival benefit of 
starting ART early during TB treatment is clear5,6 and outweighs the higher cost. Starting 
ART during TB treatment results in substantial increases in survival at moderate cost. 
However, in patients with CD4+ counts ≥50cells/mm3, the best time to initiate ART during 
TB treatment is less clear as survival was similar among patients initiated on ART in 
Arms-1 and-2. Cost-analysis could be used to decide between early and late initiation of 
ART during TB treatment in these patients.
In countries like South Africa where a cost-effectiveness threshold has not been established, 
GDP per capita is used to decide the cost-effectiveness of interventions. Interventions 
costing between one and three times annual GDP per capita are considered cost-effective. 
The cost per death averted in moving from sequential to late integrated treatment was 
estimated at $4199. This is below annual GDP per capita in South Africa in 2009 ($5758 at 
2009 prices). As the cost per death averted is lower that the annual GDP per capita, late 
integration of ART into TB treatment is cost-effective for South Africa.
Our cost analysis suggests that late initiation of ART during TB treatment (Arm-2) is the 
optimal strategy for patients with CD4+ ≥50cells/mm3, especially in resource constrained 
settings.
Cost of the various options
The largest driver of costs in all three arms was laboratory investigations, which were done 
routinely every 6 months, and when toxicity was suspected. Some of the tests are done 
routinely in a care setting, and some were specific to the research setting. Safety tests were 
repeated until safety parameters returned to normal. These costs will be lower in routine 
settings, with less frequent testing. The differences in ART and investigations costs are 
likely to shrink as duration on ART increases and ART prices decrease over time.
The cost of hospitalization per patient hospitalized was lowest in Arm-1, higher in 
Arm-2and much higher in Arm-3. Hospitalization contributed 22.4% of the total cost in 
Arm-3, due to the larger number of patients hospitalized and longer duration of hospital 
stays among patients in this group. While outpatient costs in Arms 1 and 2 are higher, these 
arms reduce the burden on the hospital system and associated costs. The Department of 
Health should be expecting to spend approximately $1086 per patient hospitalized, if a 
strategy of starting ART after the intensive phase of TB treatment adopted.
The difference in cost between Arms-1 and-2 is small, but given the large numbers of TB-
HIV co-infected patients in South Africa, the choice of late over early initiation of ART 
could lead to substantial savings.
Based on a coverage rate of 70% and an estimated 270 000 HIV-TB co-infected people in 
South Africa28, an estimated difference in cost of $3.11 per month between Arm-1 and 
Arm-2 equates to a total saving of more than $7 million per annum in South Africa through 
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selecting late integration of ART rather than early integration. This assumes that all patients 
had drug susceptible pulmonary TB.
Comparison of costs to other settings
The costs in this study were higher than published reports from HIV-only treatment 
programs.15,16 This is due to inclusion of hospitalization costs in our analysis. Some 
differences are country-specific, as hospital and labor costs are relatively high in South 
Africa. Importantly, our cost estimates were in a clinical trial context, with more frequent 
visits (monthly) and laboratory monitoring and more staff time per patient than in routine 
care settings.26 We endeavored to provide enough detail on resource utilization and various 
cost scenarios in our sensitivity analysis to enable generalizability of our findings to other 
countries. Though the total cost estimate in this clinical trial is higher than in routine care 
settings, the relative difference in price between the three treatment strategies is likely to 
translate to other settings.
A recent study by the Clinton Health Access Initiative (CHAI) found that the total cost of 
treating HIV in South African facilities was $682 per annum, considerably higher than the 
average for four other African countries, which was $200 per annum.12 This equates to 
$1023 for 18 months, lower than the cost estimated in this study. However, the CHAI study 
did not include hospital costs, or TB-related costs which were included in this analysis. The 
cost of providing HIV-treatment in PEPFAR-supported programs in 43 clinics in Botswana, 
Ethiopia, Nigeria, Uganda, and Vietnam was $880 per annum, or $1320 over 18 months. 
These estimates did not include costs of hospitalization and management of TB.16
Costing of a single ART clinic in Haiti concluded that co-treatment of TB and HIV involved 
a small increase in cost and physician time compared with treating HIV alone, and suggested 
integration of TB and ART as a way to conserve physician time.29
Study limitations
Our patient population was ambulant and relatively healthy. The costs might not be 
generalizable to populations with higher morbidity or patients with non-pulmonary TB. The 
most important limitation is the short follow-up, of 18 months. ART monthly costs decline 
after 12 months.30,31 The short duration of the study therefore likely inflated median 
monthly cost. Monthly ART costs are likely to be similar in all arms at later time points 
since all patients will be receiving ART, leading to the shrinkage of cost differences 
associated with ART provision between the arms.
The study was done at one site only, but the costs are generalizable to other outpatient sites. 
Hospitalization costs may be underestimated as only average medication cost while 
hospitalized was included. If patients required atypical and expensive medications not 
included on the Essential Medicines List applicable in the public sector, these were not 
included.
The small number of patients with IRIS in the laboratory sample may have led to inaccurate 
estimates of laboratory costs for these patients. While laboratory costs were the biggest cost 
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driver, a major limitation of our study is that these results are not readily generalizable to a 
clinical care setting as most of the laboratory tests were research related safety assessments.
New technologies have been adopted in South Africa for TB diagnosis and resistance testing 
since this clinical trial. The introduction of Xpert MTB/RIF will alter the costs estimates.
Conclusion
Current WHO recommendations call for initiating ART in all TB-HIV co-infected patients 
irrespective of CD4+ count. As more co-infected patients initiate ART, data on the cost 
effectiveness of initiating ART during TB therapy becomes important. This study provides 
health system utilization and cost data associated with starting ART during TB treatment 
with implications for health policy makers and funders.
The SAPiT4,6 CAMELIA,32 and ACTG5 trials have shown that starting ART during TB 
treatment saves lives and this analysis shows that starting ART during TB treatment is cost-
effective. Late initiation of ART during TB and HIV treatment for patients with CD4+ 
counts≥50cells/mm3 is the most cost-effective. Cost-effectiveness is only one consideration 
in starting ART in HIV-TB co-infected patients. The efficacy of the intervention and 
practical challenges of implementation of integrated services, especially in resource limited 
settings, should also be considered.
In sub-Saharan Africa, where public sector hospitals are overburdened, the reduction of the 
burden on a struggling hospital system by starting ART during TB therapy needs to be 
emphasized.
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Table 1
Unit costs of inputs and resource utilization by treatment arm
Unit costs of inputs in US $ Unit cost
Antiretroviral therapy
  Cost of first line ART regimen (per patient per month): didanosine, lamivudine, 
efavirenz
47.17
Laboratory tests (cost per test)
  CD4+ count 8.51
  HIV viral load 40.16
  Chest radiograph 11.91
  Liver function test 39.41
  Full blood count 6.47
  Urine & Electrolytes 19.33
Visit costs
  Average cost of unscheduled consultation 23.68
  Cost per missed visit (cost of tracing)3 6.16
Hospitalizations
  Cost per hospital day (level 2 hospital) 45.65
Costs in different arms Arm-1
(N=214)
Arm-2
(N= 215)
Arm-3
(N=213)
  Median monthly cost of second line ART (for patients on second-line) 73.45 85.27 85.27
Outpatient visit costs 1
  Average staff cost per ART consultation (clinician) 20.79 20.10 20.10
  Average staff cost per ART consultation (professional nurse)2 16.49 16.49 16.49
  Average staff cost per tuberculosis only consultation (clinician) 13.93 14.01 14.01
  Total cost of scheduled ART consultations over 18 months 393.57 386.08 386.08
Hospitalizations
  Average “other costs” per hospital admission3 120.12 108.81 146.08
Resource utilization
Number of patients with: n (%) n (%) n (%)
  More than one missed visit 29 (13.6%) 41 (19.1%) 47 (22.1%)
  More than one unscheduled consultation in first 3 months of tuberculosis treatment. 57 (26.6%) 13 (6.1%) 4 (1.9%)
  Switched to second line ART regimen 10 (4.7%) 8 (3.7%) 7 (3.3%)
  Did not initiate ART 15 (7.0%) 52 (24.2%) 77 (36.1%)
  Multidrug resistant tuberculosis 13 (6.1%) 8 (3.7%) 9 (4.2%)
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Unit costs of inputs in US $ Unit cost
  Immune reconstitution syndrome 43 (20.1%) 18 (8.4%) 20 (9.4%)
  Serious adverse events 52 (24.3%) 43 (20.0%) 62 (29.1%)
  Hospitalization 40 (18.7%) 30 (14.0%) 46 (21.6%)
  More than 5 days hospitalized 26 (12.2%) 21 (9.8%) 36 (16.9%)
Total number of N N N
  Hospital days 869 519 1241
  Patient months 3019 2836 2703
Median (IQR) Median (IQR) Median (IQR)
Number of unscheduled consultations 1 (1–3) 1 (1–2) 1 (1–3)
Time to ART regimen switch (months) 8.5 (3.5–10.9) 11.8 (9.1–12.5) 8.2 (5.3,9.0)
Length of tuberculosis treatment (days) 204 (196–253) 202 (194–253) 198 (182–252)
Number of CD4+ count tests 5 (4 – 6) 6 (4 – 6) 5 (3–6)
Number of viral load tests 4.5 (3 – 5) 5 (3–5) 4 (2–5)
Rate (per 100 person years)
Rate of hospitalization 18.2 15.5 23.0
ART: Antiretroviral treatment
All costs in 2009 US dollars
1
The staff cost includes the cost of all categories of staff that deal directly with the patient (reception, nursing staff, clinicians and counsellors). The 
cost of a visit is determined by the length of the visit as well as the salary of the type of staff member conducting the consultation.
2
Professional nurses saw all stable patients for scheduled consultations from the eighth month of ART treatment onwards. Clinicians saw patients 
at regular scheduled intervals, following CD4+ count and viral load tests.
3
Includes the cost of transportation to hospital, CAPRISA staff cost of admission and follow-up while in hospital.
Source of safety laboratory test prices: National Health Laboratory Services (2009)
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